Replies to post #5765 on Cellectar Biosciences Inc (CLRB)

[Sunofwolf]

It's ahead of schedule!

[Crusader]

July first is the earliest Phase 2 Update,

http://cellectar.com/pdc-pipeline/

I will post a better chart from the company:

"...In addition, the company recently brought forward guidance for the initiation of its NCI-supported Phase II trial in multiple myeloma and other selected hematologic cancers to the first quarter of 2017. The company expects that all patients will receive a single dose of CLR 131 at 25 mCi/m2 infused over approximately 30 minutes, with the option of a second 25 mCi/m2 dose 75-180 days later, based upon physician assessment. The Phase II study will be conducted in up to 15 centers across the United States and Cellectar anticipates initial efficacy data as early as the second half of 2017..."